Abstract
Purpose :
To identify visual and anatomical outcome of intravitreal OZURDEX implant for post-operative cystoid macular oedema which did not respond to topical treatment.
Methods :
Retrospective single practice data analysis from an electronic medical record system of 30 eyes (30 patients) with persistent post-operative cystoid macular oedema (CMO) receiving Intravitreal OZURDEX Implant. All cases had routine small incision cataract surgery (Phacoemulsification with IOL) without posterior capsule related complication within the last 52 weeks and already received four to eight weeks of topical treatment with steroid and/or non-steroidal anti-inflammatory drops but their visual acuity and cystoid macular oedema were not improved. Patients were symptomatic with blurred vision. ETDRS vision was recorded and CMO was identified by presence of intraretinal fluid at Optical Coherence Tomography (OCT).
Results :
Best-corrected visual acuity (BCVA) by using ETDRS chart improved from 57.4 letters at base line to 68.23 letters at 4-8 weeks and 67.87 letters at 52 weeks after receiving OZURDEX intravitreal implant. Mean central retinal thickness (CRT) decreased from 469.67um to 269um at 52 weeks. There was mean BCVA gain of 10.83 ETDRS letters at 4-8 weeks and 10.47 letters at 52 weeks. Mean reduction of CRT was 200.67um at week 52. 46.67% required single OZURDEX implant and no recurrence of CMO. They were discharged at 52 weeks. 53.33% had recurrence of CMO. 26.67% of cases required 2 OZURDEX implants and 10% required 3 implants. 13.33% were identified as intraocular pressure (IOP) higher than 21mmHg, in which 50% received topical anti-glaucoma drops. There was no other complication and none required glaucoma filtering surgery.
Conclusions :
OZURDEX intravitreal implant administered for post-operative cystoid macular oedema which did not respond to topical treatment improved visual acuity and macular morphology. OZURDEX treatment will prevent visual and structural consequences caused by chronic persistent macular oedema in this group of patients.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.